Taiwan Pharma Industry Must Adapt To Changes
Taiwan's pharmaceutical industry has been steadily developing andincreasing its market share, but the industry is now reaching a new development and marketing stage, according to local experts. Traditionally oriented to the domestic market, it must now face strong international competition.
The total value of pharmaceutical exports from Taiwan was nearly $95 million in 1996, up 23% on 1995 but, according to Customs Department statistics, the value of pharmaceutical imports that same year was $810 million, a rise of over 18% on the previous year.
According to Taiwan's Ministry of Trade, the imbalance can be attributed to several factors, among them being that:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze